Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC <li /> <str ...

A mother leaves her career to care for her son with cerebral palsy full-time. An adult sibling spends their days navigating the complexities of caregiving for their brother with a disability. A ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

DUBLIN--(BUSINESS WIRE)--The "Brain Tumor Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Brain Tumor Therapeutics is ...

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR ... Crispr reported a 12% decrease in operating expenses in the first 9 months of 2024, when compared against the ...

The Delhi government’s vigilance department has asked the Public Works Department (PWD) to submit a report on the allegations ... 2023 when allegations over expenses incurred on its renovation ...